Literature DB >> 27217398

Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in Mice.

Junichi Omura1, Kimio Satoh1, Nobuhiro Kikuchi1, Taijyu Satoh1, Ryo Kurosawa1, Masamichi Nogi1, Tomohiro Otsuki1, Katsuya Kozu1, Kazuhiko Numano1, Kota Suzuki1, Shinichiro Sunamura1, Shunsuke Tatebe1, Tatsuo Aoki1, Koichiro Sugimura1, Satoshi Miyata1, Yasushi Hoshikawa1, Yoshinori Okada1, Hiroaki Shimokawa2.   

Abstract

RATIONALE: Endothelial AMP-activated protein kinase (AMPK) plays an important role for vascular homeostasis, and its role is impaired by vascular inflammation. However, the role of endothelial AMPK in the pathogenesis of pulmonary arterial hypertension (PAH) remains to be elucidated.
OBJECTIVE: To determine the role of endothelial AMPK in the development of PAH. METHODS AND
RESULTS: Immunostaining showed that endothelial AMPK is downregulated in the pulmonary arteries of patients with PAH and hypoxia mouse model of pulmonary hypertension (PH). To elucidate the role of endothelial AMPK in PH, we used endothelial-specific AMPK-knockout mice (eAMPK(-/-)), which were exposed to hypoxia. Under normoxic condition, eAMPK(-/-) mice showed the normal morphology of pulmonary arteries compared with littermate controls (eAMPK(flox/flox)). In contrast, development of hypoxia-induced PH was accelerated in eAMPK(-/-) mice compared with controls. Furthermore, the exacerbation of PH in eAMPK(-/-) mice was accompanied by reduced endothelial function, upregulation of growth factors, and increased proliferation of pulmonary artery smooth muscle cells. Importantly, conditioned medium from endothelial cells promoted pulmonary artery smooth muscle cell proliferation, which was further enhanced by the treatment with AMPK inhibitor. Serum levels of inflammatory cytokines, including tumor necrosis factor-α and interferon-γ were significantly increased in patients with PAH compared with healthy controls. Consistently, endothelial AMPK and cell proliferation were significantly reduced by the treatment with serum from patients with PAH compared with controls. Importantly, long-term treatment with metformin, an AMPK activator, significantly attenuated hypoxia-induced PH in mice.
CONCLUSIONS: These results indicate that endothelial AMPK is a novel therapeutic target for the treatment of PAH.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  cell proliferation; cytokines; inflammation; metformin; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27217398     DOI: 10.1161/CIRCRESAHA.115.308178

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  36 in total

Review 1.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

2.  AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension.

Authors:  Jiao Zhang; Jianjie Dong; Marcy Martin; Ming He; Brendan Gongol; Traci L Marin; Lili Chen; Xinxing Shi; Yanjun Yin; Fenqing Shang; Yan Wu; Hsi-Yuan Huang; Jin Zhang; Yu Zhang; Jian Kang; Esteban A Moya; Hsien-Da Huang; Frank L Powell; Zhen Chen; Patricia A Thistlethwaite; Zu-Yi Yuan; John Y-J Shyy
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

Review 3.  Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?

Authors:  Thenappan Thenappan; Alexander Khoruts; Yingjie Chen; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

Review 4.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

5.  PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension.

Authors:  Yapeng Cao; Xiaoyu Zhang; Lina Wang; Qiuhua Yang; Qian Ma; Jiean Xu; Jingjing Wang; Laszlo Kovacs; Ramon J Ayon; Zhiping Liu; Min Zhang; Yaqi Zhou; Xianqiu Zeng; Yiming Xu; Yong Wang; David J Fulton; Neal L Weintraub; Rudolf Lucas; Zheng Dong; Jason X-J Yuan; Jennifer C Sullivan; Louise Meadows; Scott A Barman; Chaodong Wu; Junmin Quan; Mei Hong; Yunchao Su; Yuqing Huo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

6.  Activation of AMPK inhibits Galectin-3-induced pulmonary artery smooth muscle cells proliferation by upregulating hippo signaling effector YAP.

Authors:  Qianqian Zhang; Wenge Li; Yanting Zhu; Qingting Wang; Cui Zhai; Wenhua Shi; Wei Feng; Jian Wang; Xin Yan; Limin Chai; Yuqian Chen; Cong Li; Pengtao Liu; Manxiang Li
Journal:  Mol Cell Biochem       Date:  2021-04-02       Impact factor: 3.396

7.  AMP-Kinase Dysfunction Alters Notch Ligands to Impair Angiogenesis in Neonatal Pulmonary Hypertension.

Authors:  Ujala Rana; Emily Callan; Brianna Entringer; Teresa Michalkiewicz; Amit Joshi; Abdul K Parchur; Ru-Jeng Teng; Girija G Konduri
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

8.  Lung omics signatures in a bronchopulmonary dysplasia and pulmonary hypertension-like murine model.

Authors:  Amrit Kumar Shrestha; Vashisht Y N Gopal; Renuka T Menon; Joseph L Hagan; Shixia Huang; Binoy Shivanna
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-07-26       Impact factor: 5.464

Review 9.  AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System.

Authors:  Ian P Salt; D Grahame Hardie
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

Review 10.  Lessons from Cancer Metabolism for Pulmonary Arterial Hypertension and Fibrosis.

Authors:  SeungHye Han; Navdeep S Chandel
Journal:  Am J Respir Cell Mol Biol       Date:  2021-08       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.